GOSS — Gossamer Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728117 ·
Last close
$0.17
Market Cap
$83.10M
52W High
$0.38
52W Low
$0.11
ADV30
36,977,540
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 16,955,000 | — | -44,866,000 | -46,664,000 | 128,899,000 | 41,028,000 | 290,382,000 |
| Dec 2025 | 13,799,000 | — | -46,040,000 | -47,238,000 | 172,249,000 | 37,732,000 | 295,009,000 |
| Sep 2025 | 13,294,000 | — | -41,638,000 | -48,221,000 | 208,820,000 | 8,933,000 | 291,153,000 |
| Jun 2025 | 11,489,000 | — | -38,765,000 | -38,273,000 | 240,925,000 | 26,309,000 | 287,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,263,000
Investing CF
$175,902,000
Financing CF
$6,433,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,485,602,000
Inventory
—
Receivables
$9,252,000
ST Investments
$58,187,000
EBIT TTM
$-169,486,000
Pretax Income TTM
$-180,484,000
Interest Exp TTM
$10,998,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$55,537,000
EBITDA
$-171,286,000
Free Cash Flow
$-97,250,872
Enterprise Value
$143,499,024
Total Cash
$99,215,000
Total Debt
$202,932,992
Shares Out
488,846,722
Trailing EPS
$-0.79
Book Value
$-0.69
ROE
—
ROA
-52.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,471,000 | -163,253,000 | -170,370,000 | 172,249,000 | 295,009,000 | — | -171,266,000 |
| Dec 2024 | 114,701,000 | -59,919,000 | -56,528,000 | 315,292,000 | 285,800,000 | — | -3,468,000 |
| Dec 2023 | 0 | -173,759,000 | -179,817,000 | 311,916,000 | 249,147,000 | — | -159,158,000 |
| Dec 2022 | 0 | -218,528,000 | -229,378,000 | 272,450,000 | 260,373,000 | — | -187,032,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$10,136,000
NetIncome TTM
$-190,421,000
OpCashFlow TTM
$0
Assets (Latest)
$315,292,000
Forward EPS
$-0.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals, Inc. | $83.22M | $1.21 | — |
| RLYB | Rallybio Corp | $84.54M | $15.93 | — |
| BMEA | Biomea Fusion, Inc. | $84.59M | $1.17 | — |
| LFVN | Lifevantage Corp | $81.12M | $6.43 | — |
| ACET | Adicet Bio, Inc. | $85.16M | $9.11 | — |
News headlines (Yahoo Finance, 1h cache)
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update
2026-08-01 02:06 · Yahoo
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2026-07-30 14:00 · Yahoo
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment
2026-07-28 08:19 · Yahoo
Gossamer Bio shares jump after FDA update and seralutinib rights return
2026-07-27 13:33 · Yahoo
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
2026-07-27 11:00 · Yahoo
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes
2026-07-02 14:08 · Yahoo
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
2026-07-01 13:00 · Yahoo
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk
2026-06-18 13:08 · Yahoo
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...
2026-06-17 22:19 · Yahoo
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
2026-06-11 01:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.